CClinicalTrials.gg
CompletedNCT06212128RAPIDOUpdated Apr 30, 2026

RAPIDO vs LCRT vs Upfront Surgery - a Prospective Cohort Study

An observational study in Rectal Cancer, sponsored by Sengkang General Hospital. Completed. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Sengkang General Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
57
Ages
21 Years to 99 Years
Sex
All
01

Study summary

Aim: We evaluated the surgical outcomes of 3 groups of patients with rectal cancers - RAPIDO vs standard long course radiotherapy (LCRT) vs upfront surgery to objectively determine the effects of TNT on TME.

Methods: A review of prospectively collected data was performed for patients who have rectal cancer and underwent low anterior resection from January 2016 to May 2022. Data on patient demographics, disease staging, peri-operative details and up to 2-year follow-up outcomes were analysed. The surgical and oncological outcomes were compared. Patients were followed up until 31 May 2022.

Read the detailed description

A review of prospectively collected data was performed for all patients who were diagnosed with rectal cancer and who underwent ultra-low anterior resection (ULAR) from January 2016 to May 2022 in a single institution in Singapore. Exclusion criteria of this study included patients who underwent emergency surgery and patients with unresectable metastatic disease at presentation. All patients were discussed at multi-disciplinary tumour board for recommendation and decision of the respective treatment protocols. Patients were analysed in 3 main categories: neoadjuvant therapy per RAPIDO protocol, LCRT and upfront surgery. Patients under RAPIDO group underwent 25Gy/5 sessions of short course radiotherapy followed by 6 cycles of neoadjuvant XELOX similar to that of the RAPIDO trial protocol while patients in LCRT group underwent conventional 50Gy/25-28 sessions of long course radiotherapy with concurrent oral capecitabine. All cases were performed by 7 consultant-grade colorectal surgeons in the department.

Patient demographics and peri-operative details were collected. Histopathological stage of disease was in accordance with the American Joint Committee on Cancer (AJCC) staging manual after surgical resection with review of the resected specimen by consultant-grade pathologists who were blinded to the type of pre-operative treatment the patients received.

Primary outcome for the study was the operative time required for primary resection of rectal tumour. If combined surgery was performed for oligometastatic disease, we removed the operating time for non-rectal component as this was separately defined in the operation notes.

Secondary outcomes included the intraoperative blood loss, duration to stoma function, failure to remove urinary catheter, presence of post-operative ileus, duration of hospitalisation after surgery. Presence of stoma function was defined as enteric content of significant amount (>200ml or presence of formed faecal material). Failure of removal of urinary catheter is defined as acute urinary retention requiring re-insertion of catheter post-operatively. Post-operative ileus is defined as ileus which persist beyond 7 days from operation.

Follow-up outcomes and data for patients were collected until 31 May 2022. Local-regional recurrence was defined as the first clinical, radiologic and/or pathologic evident tumour of the same histological type at the region of the anastomosis and pelvis. Distant recurrent was defined similarly at sites outside primary malignancy such as liver, lung, bone, brain, para-aortic region. Presence of recurrence in patients was recorded, disease-free interval was calculated in months from date of surgery to date of recurrence.

Statistical analysis All data was analysed with SPSS version 28 (SPSS Inc, Chicago, III). Patients with missing data were accounted for and excluded during the statistical analysis of this data. Categorical variables were presented as percentages while median and interquartile ranges were presented for continuous variables. Differences between categorical variables were analysed using either Chi-square or Student t-test. Differences between continuous variables were treated as non-parametric and analysed using either Kruskal Willis or Mann-Whitney U. Two-sided tests were used, with p value \<0.05 treated as significant. Kaplan Meier curves were plotted for survival data including disease free survival and overall survival.

02

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Rectal Cancer
  • Surgical outcomes
  • Neoadjuvant treatment
03

In context

Rectal Neoplasms

1,762 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.

This study's enrollment of 57 is below the median of 160 across 413 observational studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

Sengkang General Hospital is the lead sponsor of 16 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

as above

Inclusion criteria

  • diagnosed with rectal cancer
  • due to undergo ultra-low anterior resection (ULAR)

Exclusion criteria

Exclusion Criteria:

  • emergency surgery
  • unresectable metastatic disease at presentation
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
57 participants (actual)
Target follow-up
36 Months
Patient registry
Yes

Groups and cohorts

  • RAPIDO TNT

    neoadjuvant therapy per RAPIDO protocol

    Combination Product: RAPIDO TNT

  • LCRT

    long course chemoradiotherapy

    Combination Product: LCRT

  • upfront surgery

    directly went for surgery after diagnosis of rectal cancer

Interventions

  • Combination productRAPIDO TNT

    neoadjuvant therapy per RAPIDO protocol (Patients under RAPIDO group underwent 25Gy/5 sessions of short course radiotherapy followed by 6 cycles of neoadjuvant XELOX similar to that of the RAPIDO trial protocol)

  • Combination productLCRT

    LCRT group underwent conventional 50Gy/25-28 sessions of long course radiotherapy with concurrent oral capecitabine

06

What researchers measure

Primary outcomes

  1. operative time required for primary resection of rectal tumour

    operative time in minutes

    Time frame: 1 day

Secondary outcomes

  1. intraoperative blood loss

    in ml

    Time frame: 30 days post surgery

  2. duration to stoma functioning

    in days

    Time frame: 14 days post surgery

  3. failure to remove urinary catheter

    yes/no, and in days to successful removal

    Time frame: 14 days post surgery

  4. presence of post op ileus (defined as >7 days intolerance to diet or no stoma output from time of operation)

    yes/no

    Time frame: 14 days post surgery

  5. duration of hospitalisation

    in days from time of surgery

    Time frame: 30 days after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06212128
Lead sponsor
Sengkang General Hospital
Responsible party
Koh Hong Xiang Frederick (Consultant, Sengkang General Hospital) — Principal investigator
First posted
Jan 18, 2024
Start date
Jan 1, 2016
Primary completion
May 31, 2022
Completion
Mar 30, 2026
Last update
Apr 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion